{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:42:13Z","timestamp":1778946133454,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004008","name":"Istituto Superiore di Sanit\u00e0","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004008","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The lack of specificity and high degree of false positive and false negative rates when using mammographic screening for detecting early-stage breast cancer is a critical issue. Blood-based molecular assays that could be used in adjunct with mammography for increased specificity and sensitivity could have profound clinical impact. Our objective was to discover and independently verify a panel of candidate blood-based biomarkers that could identify the earliest stages of breast cancer and complement current mammographic screening approaches.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used affinity hydrogel nanoparticles coupled with LC-MS\/MS analysis to enrich and analyze low-abundance proteins in serum samples from 20 patients with invasive ductal carcinoma (IDC) breast cancer and 20 female control individuals with positive mammograms and benign pathology at biopsy. We compared these results to those obtained from five cohorts of individuals diagnosed with cancer in organs other than breast (ovarian, lung, prostate, and colon cancer, as well as melanoma) to establish IDC-specific protein signatures. Twenty-four IDC candidate biomarkers were then verified by multiple reaction monitoring (LC-MRM) in an independent validation cohort of 60 serum samples specifically including earliest-stage breast cancer and benign controls (19 early-stage (T1a) IDC and 41 controls).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In our discovery set, 56 proteins were increased in the serum samples from IDC patients, and 32 of these proteins were specific to IDC. Verification of a subset of these proteins in an independent cohort of early-stage T1a breast cancer yielded a panel of 4 proteins, ITGA2B (integrin subunit alpha IIb), FLNA (Filamin A), RAP1A (Ras-associated protein-1A), and TLN-1 (Talin-1), which classified breast cancer patients with 100% sensitivity and 85% specificity (AUC of 0.93).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Using a nanoparticle-based protein enrichment technology, we identified and verified a highly specific and sensitive protein signature indicative of early-stage breast cancer with no false positives when assessing benign and inflammatory controls. These markers have been previously reported in cell-ECM interaction and tumor microenvironment biology. Further studies with larger cohorts are needed to evaluate whether this biomarker panel improves the positive predictive value of mammography for breast cancer detection.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13058-020-01373-9","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T11:03:45Z","timestamp":1606907025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection"],"prefix":"10.1186","volume":"22","author":[{"given":"Claudia","family":"Fredolini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khyatiben V.","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Paris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina M.","family":"Chapple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine A.","family":"Tsantilas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony J.","family":"Tegeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystine","family":"Garcia-Mansfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Tamburro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weidong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuele","family":"Massarut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Facchiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Belluco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruggero","family":"De Maria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Garaci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance","family":"Liotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel F.","family":"Petricoin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1360-6039","authenticated-orcid":false,"given":"Patrick","family":"Pirrotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"issue":"9","key":"1373_CR1","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrclinonc.2016.50","volume":"13","author":"Y Shieh","year":"2016","unstructured":"Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ. Population-based screening for cancer: hope and hype. Nat Rev Clin Oncol. 2016;13(9):550\u201365.","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 1","key":"1373_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1258\/jms.2012.012083","volume":"19","author":"S Hofvind","year":"2012","unstructured":"Hofvind S, Ponti A, Patnick J, Ascunce N, Njor S, Broeders M, et al. False-positive results in mammographic screening for breast cancer in Europe: a literature review and survey of service screening programmes. J Med Screen. 2012;19(Suppl 1):57\u201366.","journal-title":"J Med Screen"},{"key":"1373_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13058-015-0525-z","volume":"17","author":"M L\u00f8berg","year":"2015","unstructured":"L\u00f8berg M, Lousdal ML, Bretthauer M, Kalager M. Benefits and harms of mammography screening. Breast Cancer Res. 2015;17:63.","journal-title":"Breast Cancer Res"},{"key":"1373_CR4","unstructured":"Joy JE, Penhoet EE, Petitti DB, National Cancer Policy Board (U.S.). Committee on New Approaches to Early Detection and Diagnosis of Breast Cancer., National Research Council (U.S.). Policy and Global Affairs., National Research Council (U.S.). Board on Science Technology and Economic Policy. Saving women\u2019s lives: strategies for improving breast cancer detection and diagnosis. Washington, D.C.: National Academies Press; 2005. xxi, 361 p. p."},{"issue":"11","key":"1373_CR5","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1001\/jamainternmed.2015.5231","volume":"175","author":"CD Lehman","year":"2015","unstructured":"Lehman CD, Wellman RD, Buist DS, Kerlikowske K, Tosteson AN, Miglioretti DL, et al. Diagnostic accuracy of digital screening mammography with and without computer-aided detection. JAMA Intern Med. 2015;175(11):1828\u201337.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"1373_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1148\/radiol.2017161519","volume":"283","author":"BL Sprague","year":"2017","unstructured":"Sprague BL, Arao RF, Miglioretti DL, Henderson LM, Buist DS, Onega T, et al. National performance benchmarks for modern diagnostic digital mammography: update from the Breast Cancer Surveillance Consortium. Radiology. 2017;283(1):59\u201369.","journal-title":"Radiology."},{"issue":"2","key":"1373_CR7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1148\/radiol.12112074","volume":"264","author":"SR Hoff","year":"2012","unstructured":"Hoff SR, Abrahamsen AL, Samset JH, Vigeland E, Klepp O, Hofvind S. Breast cancer: missed interval and screening-detected cancer at full-field digital mammography and screen-film mammography-- results from a retrospective review. Radiology. 2012;264(2):378\u201386.","journal-title":"Radiology."},{"issue":"4","key":"1373_CR8","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.mayocp.2013.12.014","volume":"89","author":"AT Wang","year":"2014","unstructured":"Wang AT, Vachon CM, Brandt KR, Ghosh K. Breast density and breast cancer risk: a practical review. Mayo Clin Proc. 2014;89(4):548\u201357.","journal-title":"Mayo Clin Proc"},{"key":"1373_CR9","unstructured":"NationalCancerInstitute(NCI). Early Detection Research Network [Available from: https:\/\/edrn.nci.nih.gov\/biomarkers]. Accessed 2 July 2020."},{"issue":"4 Suppl","key":"1373_CR10","first-page":"49","volume":"34","author":"M Di Seri","year":"1990","unstructured":"Di Seri M, Manna A, Sci\u00f2 M, Marchei GG, De Benedetto A, Reale MG. Evaluation of the new marker CA 549 versus CA 15-3 in neoplastic and non-neoplastic disease of the breast. J Nucl Med Allied Sci. 1990;34(4 Suppl):49.","journal-title":"J Nucl Med Allied Sci"},{"issue":"47","key":"1373_CR11","doi-asserted-by":"publisher","first-page":"19178","DOI":"10.1021\/ja207515j","volume":"133","author":"D Tamburro","year":"2011","unstructured":"Tamburro D, Fredolini C, Espina V, Douglas TA, Ranganathan A, Ilag L, et al. Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers. J Am Chem Soc. 2011;133(47):19178\u201388.","journal-title":"J Am Chem Soc"},{"issue":"4","key":"1373_CR12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1208\/s12248-010-9211-3","volume":"12","author":"C Fredolini","year":"2010","unstructured":"Fredolini C, Meani F, Luchini A, Zhou W, Russo P, Ross M, et al. Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. AAPS J. 2010;12(4):504\u201318.","journal-title":"AAPS J"},{"issue":"4","key":"1373_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/pmic.201500164","volume":"16","author":"A Conti","year":"2016","unstructured":"Conti A, Fredolini C, Tamburro D, Magagnoli G, Zhou W, Liotta LA, et al. Identification of novel candidate circulating biomarkers for malignant soft tissue sarcomas: correlation with metastatic progression. Proteomics. 2016;16(4):689\u201397.","journal-title":"Proteomics."},{"issue":"1","key":"1373_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1600-0625.2010.01187.x","volume":"20","author":"C Longo","year":"2011","unstructured":"Longo C, Gambara G, Espina V, Luchini A, Bishop B, Patanarut AS, et al. A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum. Exp Dermatol. 2011;20(1):29\u201334.","journal-title":"Exp Dermatol"},{"issue":"4","key":"1373_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14789450.2018.1450631","volume":"15","author":"B Kim","year":"2018","unstructured":"Kim B, Araujo R, Howard M, Magni R, Liotta LA, Luchini A. Affinity enrichment for mass spectrometry: improving the yield of low abundance biomarkers. Expert Rev Proteomics. 2018;15(4):353\u201366.","journal-title":"Expert Rev Proteomics"},{"key":"1373_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.aca.2012.06.033","volume":"740","author":"AL Capriotti","year":"2012","unstructured":"Capriotti AL, Caruso G, Cavaliere C, Piovesana S, Samperi R, Lagan\u00e0 A. Comparison of three different enrichment strategies for serum low molecular weight protein identification using shotgun proteomics approach. Anal Chim Acta. 2012;740:58\u201365.","journal-title":"Anal Chim Acta"},{"key":"1373_CR17","first-page":"321","volume":"383","author":"V Espina","year":"2007","unstructured":"Espina V, Wulfkuhle JD, Calvert VS, Petricoin EF 3rd, Liotta LA. Reverse phase protein microarrays for monitoring biological responses. Methods Mol Biol. 2007;383:321\u201336.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"1373_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/nbt.1524","volume":"27","author":"VA Fusaro","year":"2009","unstructured":"Fusaro VA, Mani DR, Mesirov JP, Carr SA. Prediction of high-responding peptides for targeted protein assays by mass spectrometry. Nat Biotechnol. 2009;27(2):190\u20138.","journal-title":"Nat Biotechnol"},{"issue":"Database issue","key":"1373_CR19","doi-asserted-by":"publisher","first-page":"D655","DOI":"10.1093\/nar\/gkj040","volume":"34","author":"F Desiere","year":"2006","unstructured":"Desiere F, Deutsch EW, King NL, Nesvizhskii AI, Mallick P, Eng J, et al. The PeptideAtlas project. Nucleic Acids Res. 2006;34(Database issue):D655\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"1373_CR20","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/bioinformatics\/btq054","volume":"26","author":"B MacLean","year":"2010","unstructured":"MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 2010;26(7):966\u20138.","journal-title":"Bioinformatics."},{"key":"1373_CR21","unstructured":"H.sapiens - Plasma (Integrated). [cited March 2017]. Available from: https:\/\/pax-db.org\/dataset\/9606\/171\/."},{"key":"1373_CR22","doi-asserted-by":"crossref","unstructured":"Jacobs ES, Keating SM, Abdel-Mohsen M, Gibb SL, Heitman JW, Inglis HC, et al. Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication. J Virol . 2017;91(6):e02051\u201316.","DOI":"10.1128\/JVI.02051-16"},{"issue":"4","key":"1373_CR23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1681\/ASN.2010070722","volume":"22","author":"L Grgurevic","year":"2011","unstructured":"Grgurevic L, Macek B, Healy DR, Brault AL, Erjavec I, Cipcic A, et al. Circulating bone morphogenetic protein 1-3 isoform increases renal fibrosis. J Am Soc Nephrol. 2011;22(4):681\u201392.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1373_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017312","volume":"6","author":"I Shafat","year":"2011","unstructured":"Shafat I, Ilan N, Zoabi S, Vlodavsky I, Nakhoul F. Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels. PLoS One. 2011;6(2):e17312.","journal-title":"PLoS One"},{"issue":"Pt A","key":"1373_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.biocel.2016.10.014","volume":"81","author":"ET Goddard","year":"2016","unstructured":"Goddard ET, Hill RC, Barrett A, Betts C, Guo Q, Maller O, et al. Quantitative extracellular matrix proteomics to study mammary and liver tissue microenvironments. Int J Biochem Cell Biol. 2016;81(Pt A):223\u201332.","journal-title":"Int J Biochem Cell Biol."},{"key":"1373_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2015.09.012","volume":"35","author":"M Giussani","year":"2015","unstructured":"Giussani M, Merlino G, Cappelletti V, Tagliabue E, Daidone MG. Tumor-extracellular matrix interactions: identification of tools associated with breast cancer progression. Semin Cancer Biol. 2015;35:3\u201310.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1373_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.molonc.2009.11.003","volume":"4","author":"P Gromov","year":"2010","unstructured":"Gromov P, Gromova I, Bunkenborg J, Cabezon T, Moreira JM, Timmermans-Wielenga V, et al. Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol Oncol. 2010;4(1):65\u201389.","journal-title":"Mol Oncol"},{"issue":"2","key":"1373_CR28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.scr.2011.11.005","volume":"8","author":"MG Kolonin","year":"2012","unstructured":"Kolonin MG, Evans KW, Mani SA, Gomer RH. Alternative origins of stroma in normal organs and disease. Stem Cell Res. 2012;8(2):312\u201323.","journal-title":"Stem Cell Res"},{"key":"1373_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cellsig.2018.04.008","volume":"48","author":"M Zar\u00e0","year":"2018","unstructured":"Zar\u00e0 M, Canobbio I, Visconte C, Canino J, Torti M, Guidetti GF. Molecular mechanisms of platelet activation and aggregation induced by breast cancer cells. Cell Signal. 2018;48:45\u201353.","journal-title":"Cell Signal"},{"key":"1373_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jprot.2014.07.025","volume":"112","author":"AL Fern\u00e1ndez-Grijalva","year":"2015","unstructured":"Fern\u00e1ndez-Grijalva AL, Aguilar-Lemarroy A, Jave-Suarez LF, Guti\u00e9rrez-Ortega A, Godinez-Melgoza PA, Herrera-Rodr\u00edguez SE, et al. Alpha 2HS-glycoprotein, a tumor-associated antigen (TAA) detected in Mexican patients with early-stage breast cancer. J Proteome. 2015;112:301\u201312.","journal-title":"J Proteome"},{"issue":"6","key":"1373_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nrc2148","volume":"7","author":"W Wang","year":"2007","unstructured":"Wang W, Eddy R, Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer. 2007;7(6):429\u201340.","journal-title":"Nat Rev Cancer"},{"issue":"51","key":"1373_CR32","doi-asserted-by":"publisher","first-page":"36418","DOI":"10.1074\/jbc.M113.495713","volume":"288","author":"X Huang","year":"2013","unstructured":"Huang X, Pan Q, Sun D, Chen W, Shen A, Huang M, et al. O-GlcNAcylation of cofilin promotes breast cancer cell invasion. J Biol Chem. 2013;288(51):36418\u201325.","journal-title":"J Biol Chem"},{"issue":"2","key":"1373_CR33","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3892\/ol.2017.6413","volume":"14","author":"Y Maimaiti","year":"2017","unstructured":"Maimaiti Y, Tan J, Liu Z, Guo Y, Yan Y, Nie X, et al. Overexpression of cofilin correlates with poor survival in breast cancer: a tissue microarray analysis. Oncol Lett. 2017;14(2):2288\u201394.","journal-title":"Oncol Lett"},{"issue":"2","key":"1373_CR34","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1186\/bcr2853","volume":"13","author":"EA McSherry","year":"2011","unstructured":"McSherry EA, Brennan K, Hudson L, Hill AD, Hopkins AM. Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase. Breast Cancer Res. 2011;13(2):R31.","journal-title":"Breast Cancer Res"},{"issue":"7","key":"1373_CR35","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1091\/mbc.e08-10-1014","volume":"20","author":"EA Severson","year":"2009","unstructured":"Severson EA, Lee WY, Capaldo CT, Nusrat A, Parkos CA. Junctional adhesion molecule a interacts with Afadin and PDZ-GEF2 to activate Rap1A, regulate beta1 integrin levels, and enhance cell migration. Mol Biol Cell. 2009;20(7):1916\u201325.","journal-title":"Mol Biol Cell"},{"key":"1373_CR36","doi-asserted-by":"crossref","unstructured":"Ziegler YS, Moresco JJ, Yates JR, Nardulli AM. PLoS One. 2016;11(6):e0158296.","DOI":"10.1371\/journal.pone.0158296"},{"issue":"5","key":"1373_CR37","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","volume":"139","author":"KR Levental","year":"2009","unstructured":"Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139(5):891\u2013906.","journal-title":"Cell."},{"issue":"1","key":"1373_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10549-005-9089-4","volume":"97","author":"U Langsenlehner","year":"2006","unstructured":"Langsenlehner U, Renner W, Yazdani-Biuki B, Eder T, Wascher TC, Paulweber B, et al. Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk. Breast Cancer Res Treat. 2006;97(1):67\u201372.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1373_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.20892\/j.issn.2095-3941.2016.0086","volume":"14","author":"YL Zhang","year":"2017","unstructured":"Zhang YL, Wang RC, Cheng K, Ring BZ, Su L. Roles of Rap1 signaling in tumor cell migration and invasion. Cancer Biol Med. 2017;14(1):90\u20139.","journal-title":"Cancer Biol Med"},{"issue":"7605","key":"1373_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature18003","volume":"534","author":"P Mertins","year":"2016","unstructured":"Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534(7605):55\u201362.","journal-title":"Nature."},{"issue":"4","key":"1373_CR41","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nm.3497","volume":"20","author":"JK Mouw","year":"2014","unstructured":"Mouw JK, Yui Y, Damiano L, Bainer RO, Lakins JN, Acerbi I, et al. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat Med. 2014;20(4):360\u20137.","journal-title":"Nat Med"},{"issue":"10","key":"1373_CR42","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/nmat4009","volume":"13","author":"O Chaudhuri","year":"2014","unstructured":"Chaudhuri O, Koshy ST, Branco da Cunha C, Shin JW, Verbeke CS, Allison KH, et al. Extracellular matrix stiffness and composition jointly regulate the induction of malignant phenotypes in mammary epithelium. Nat Mater. 2014;13(10):970\u20138.","journal-title":"Nat Mater"},{"issue":"1","key":"1373_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1741-7015-4-38","volume":"4","author":"PP Provenzano","year":"2006","unstructured":"Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med. 2006;4(1):38.","journal-title":"BMC Med"},{"issue":"10","key":"1373_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013133","volume":"5","author":"Y Shen","year":"2010","unstructured":"Shen Y, Toli\u0107 N, Liu T, Zhao R, Petritis BO, Gritsenko MA, et al. Blood peptidome-degradome profile of breast cancer. PLoS One. 2010;5(10):e13133.","journal-title":"PLoS One"},{"issue":"9","key":"1373_CR45","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1074\/mcp.M113.031591","volume":"13","author":"J Cox","year":"2014","unstructured":"Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics. 2014;13(9):2513\u201326.","journal-title":"Mol Cell Proteomics"},{"issue":"4","key":"1373_CR46","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1021\/acs.jproteome.6b00645","volume":"16","author":"MR Al Shweiki","year":"2017","unstructured":"Al Shweiki MR, M\u00f6nchgesang S, Majovsky P, Thieme D, Trutschel D, Hoehenwarter W. Assessment of label-free quantification in discovery proteomics and impact of technological factors and natural variability of protein abundance. J Proteome Res. 2017;16(4):1410\u201324.","journal-title":"J Proteome Res"},{"issue":"1","key":"1373_CR47","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1038\/s41467-020-17033-7","volume":"11","author":"JE Blume","year":"2020","unstructured":"Blume JE, Manning WC, Troiano G, Hornburg D, Figa M, Hesterberg L, et al. Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona. Nat Commun. 2020;11(1):3662.","journal-title":"Nat Commun"},{"issue":"10\u201311","key":"1373_CR48","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/prca.200780174","volume":"2","author":"AG Paulovich","year":"2008","unstructured":"Paulovich AG, Whiteaker JR, Hoofnagle AN, Wang P. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin Appl. 2008;2(10\u201311):1386\u2013402.","journal-title":"Proteomics Clin Appl"},{"issue":"3","key":"1373_CR49","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1074\/mcp.M113.036095","volume":"13","author":"SA Carr","year":"2014","unstructured":"Carr SA, Abbatiello SE, Ackermann BL, Borchers C, Domon B, Deutsch EW, et al. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics. 2014;13(3):907\u201317.","journal-title":"Mol Cell Proteomics"},{"issue":"D1","key":"1373_CR50","doi-asserted-by":"publisher","first-page":"D442","DOI":"10.1093\/nar\/gky1106","volume":"47","author":"Y Perez-Riverol","year":"2019","unstructured":"Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 2019;47(D1):D442\u2013D50.","journal-title":"Nucleic Acids Res"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-01373-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-020-01373-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-01373-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T22:18:16Z","timestamp":1606947496000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-020-01373-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1373"],"URL":"https:\/\/doi.org\/10.1186\/s13058-020-01373-9","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"27 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research protocol was approved by the Ethic Committee of each Clinical Center involved, and all patients provided appropriate informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the manuscript and consented to its publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EFP, AL, and LL are co-inventors on the HN technology owned by George Mason University and might receive royalties as provided by US LAW. EFP, AL, and LL are co-founders of Ceres Nanosciences, Inc. the exclusive licensee to the HN technology, with less than 3% equity ownership interests. EFP and LL act as consultants to the Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}